Article thumbnail

Liver Progenitor Cell Line HepaRG Differentiated in a Bioartificial Liver Effectively Supplies Liver Support to Rats with Acute Liver Failure

By Geert A. A. Nibourg, Robert A. F. M. Chamuleau, Tessa V. van der Hoeven, Martinus A. W. Maas, An F. C. Ruiter, Wouter H. Lamers, Ronald P. J. Oude Elferink, Thomas M. van Gulik and Ruurdtje Hoekstra

Abstract

A major roadblock to the application of bioartificial livers is the need for a human liver cell line that displays a high and broad level of hepatic functionality. The human bipotent liver progenitor cell line HepaRG is a promising candidate in this respect, for its potential to differentiate into hepatocytes and bile duct cells. Metabolism and synthesis of HepaRG monolayer cultures is relatively high and their drug metabolism can be enhanced upon treatment with 2% dimethyl sulfoxide (DMSO). However, their potential for bioartificial liver application has not been assessed so far. Therefore, HepaRG cells were cultured in the Academic Medical Center bioartificial liver (AMC-BAL) with and without DMSO and assessed for their hepatic functionality in vitro and in a rat model of acute liver failure. HepaRG-AMC-BALs cultured without DMSO eliminated ammonia and lactate, and produced apolipoprotein A-1 at rates comparable to freshly isolated hepatocytes. Cytochrome P450 3A4 transcript levels and activity were high with 88% and 37%, respectively, of the level of hepatocytes. DMSO treatment of HepaRG-AMC-BALs reduced the cell population and the abovementioned functions drastically. Therefore, solely HepaRG-AMC-BALs cultured without DMSO were tested for efficacy in rats with acute liver failure (n = 6). HepaRG-AMC-BAL treatment increased survival time of acute liver failure rats ∼50% compared to acellular-BAL treatment. Moreover, HepaRG-AMC-BAL treatment decreased the progression of hepatic encephalopathy, kidney failure, and ammonia accumulation. These results demonstrate that the HepaRG-AMC-BAL is a promising bioartificial liver for clinical application

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3377721
Provided by: PubMed Central

Suggested articles

Citations

  1. (2009). A
  2. (2010). A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
  3. (2010). Acute liver failure.
  4. (2009). Artificial and bioartificial liver devices: present and future.
  5. (2005). Assessment and improvement of liver specific function of the AMCbioartificial liver.
  6. (2010). Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy.
  7. (1999). Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNAbinding activity of liver-enriched and growth-associated transcription factors.
  8. (2010). Brain hypoxanthine concentration correlates to lactate/pyruvate ratio but not intracranial pressure in patients with acute liver failure.
  9. (1978). Changes in DNA associated with induction of erythroid differentiation by dimethyl sulfoxide in murine erythroleukemia cells.
  10. (2006). Deaths on the liver transplant waiting list: an analysis of competing risks.
  11. (1997). Effect of cell density and epidermal growth factor on the inducible expression of CYP3A and CYP1A genes in human hepatocytes in primary culture.
  12. (2011). Effects of DMSO on gene expression in human and rat hepatocytes.
  13. (2008). Enhanced oxygen availability improves liver-specific functions of the AMC bioartificial liver.
  14. (1999). Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability.
  15. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
  16. (2008). Human ApoA-I overexpression diminishes LPSinduced systemic inflammation and multiple organ damage in mice.
  17. (1997). In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates.
  18. (1975). Induction of erythroid differentiation by dimethylsulfoxide in cells infected with Friend virus: relationship to the cell cycle.
  19. (2002). Infection of a human hepatoma cell line by hepatitis B virus.
  20. (2009). Liver transplantation for acute-on-chronic liver failure.
  21. (2009). Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes.
  22. (1994). Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver.
  23. (2003). Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices.
  24. (2008). Role of liver transplantation in acute liver failure.
  25. (2010). Stable overexpression of Pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application.
  26. (2011). The HepaRG cell line is suitable for bioartificial liver application.
  27. (2002). The pathophysiological basis of acute-onchronic liver failure.
  28. (2007). Time-related analysis of metabolic liver functions, cellular morphology, and gene expression of hepatocytes cultured in the bioartificial liver of the Academic Medical Center in Amsterdam (AMC-BAL).

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.